PORTLAND, ME--(Marketwired - April 10, 2014) - ImmuCell Corporation (NASDAQ: ICCC), an emerging animal health company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries, announced today that it has retained Lytham Partners, LLC to conduct a nationwide investor relations program.
ImmuCell has developed products that provide significant immunity bolstering benefits to newly born dairy and beef livestock. The Company has also developed products that address mastitis, the most significant cause of economic loss to the dairy industry.
The Company's approved and marketed products include:
- First Defense®, an orally delivered product for newborn calves that provides Immediate Immunity™ against bovine enteritis (calf scours) caused by E. coli and coronavirus infections. Calf scours can seriously hamper physical development of the calf, as well as its future milk and beef production capabilities.
- Wipe Out® Dairy Wipes, towelettes that are pre-moistened with a Nisin-based formulation that are used to sanitize a cow's udder before milking. Nisin is a broad-spectrum bacteriocin. During 2013, the Company initiated sales of a smaller canister format of this topical wipe intended for pets.
- California Mastitis Test (CMT), a cost-effective, on-site test for the early detection of mastitis.
The Company is also developing:
- Mast Out®, a Nisin-based treatment for subclinical mastitis in lactating dairy cows that may be used without a milk discard. Nisin is a natural antimicrobial, in contrast to traditional antibiotics that are associated with serious concerns within the scientific and medical communities that their use in production animals may be related to the development of strains of bacterial infections, commonly referred to as "superbugs" that are resistant to antibiotics used to treat infections in humans.
- First Defense® line extensions, offering additional protection against calf scours.
Michael F. Brigham, president and chief executive officer of ImmuCell Corporation, said, "We are pleased to announce today the retention of Lytham Partners to broadly introduce ImmuCell to the national investment community. We take great pride in consistently developing our products, personnel and infrastructure over the years in a conservative and cost-effective manner. We maintain a solid cash position, with minimal long-term debt and operate our business from internally generated cash flow. We have achieved positive revenue growth for six consecutive quarters and for twelve of the last thirteen quarters overall. We have developed leading-edge products and are working to gain FDA approval of Mast Out®, a novel product intended to effectively address subclinical mastitis in dairy cows. This could lessen the volume of traditional antibiotics that is used in production animals and improve milk quality and cow productivity."
Joseph Diaz, managing partner at Lytham Partners, LLC, said, "We look forward to working with the management team and the Board of Directors at ImmuCell Corporation. ImmuCell is well positioned with strong fundamental growth from its existing product lines as its Mast Out® product works its way through the FDA approval process. We believe that as the national investment community becomes increasingly aware of ImmuCell, its products, and the potential positive impact that those products can have in the animal health community, as well as on the human food chain, the valuation of the Company will approach what we believe to be a more appropriate level. We look forward to a successful collaboration."
About Lytham Partners, LLC.
Lytham Partners, LLC provides expertise and guidance to small-capitalization companies in the healthcare, technology, services, agricultural, industrial, aerospace and defense segments, as well as the consumer and capital goods industries. The firm is dedicated to generating substantive communications programs with an emphasis on developing management credibility via data, clear articulation of achievable strategic plans, and timely interaction with investors. For more information visit our website at www.lythampartners.com.
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. ImmuCell has developed products that provide significant immunity bolstering benefits to newly born dairy and beef livestock. The Company has also developed products that address mastitis, the most significant cause of economic loss to the dairy industry. Press releases and other information about the Company are available at our web-site, (http://www.immucell.com).
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to: projections of future financial performance; the scope and timing of future product development work and commercialization of our products; the future adequacy of our working capital and the availability of third party financing; the outcome of pending or anticipated applications for future regulatory approvals; factors that may affect the dairy and beef industries and future demand for our products; anticipated competitive and market conditions; and any other statements that are not historical facts. Forward-looking statements can be identified by the use of words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", "projects", "forecasts" and similar words and expressions. In addition, there can be no assurance that future developments affecting us will be those that we anticipate. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product markets, the uncertainties associated with product development, pharmaceutical-grade Nisin manufacturing, our potential reliance upon third parties for financial support, products and services, changes in laws and regulations, decision making by regulatory authorities and other risks detailed from time to time in filings we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements are based on our current expectations, but actual results may differ materially due to various factors.